FDA Brief

Warning letters Drugs

FDA warning letter to

Baxter International Inc.

High riskIssued Sep 29Posted Oct 20Center for Drug Evaluation and Research (CDER)

Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

What happened

FDA inspected Baxter Healthcare Corporation's drug manufacturing facility at 25212 W Illinois Route 120, Round Lake, from March 23 to April 2, 2026. FDA found that cephalosporin and other drug production were not completely separated in the shared building, that cephalosporin was repeatedly detected on the other side, and that environmental monitoring was inadequate and some failing samples were discarded. FDA also found inadequate sterile processing controls and an inadequate manual visual inspection program; it says Baxter recalled cefazolin lot LD175708 only after FDA contacted the company.

What FDA found

  1. Baxter did not adequately separate cephalosporin production from other drug production in a shared building, and repeated cephalosporin contamination was found on the other side.

    21 CFR 211.42(c)
  2. Baxter's environmental monitoring for cephalosporin contamination was too limited, had inadequate swab recovery, used samples beyond stability limits, and discarded failing samples.

    21 CFR 211.42(c)
  3. Baxter's sterilization and sterile processing validation was inadequate; repeated biological indicator growth was accepted, and interior surfaces were not fully exposed to the sterilizing process.

    21 CFR 211.113(b); 21 CFR 211.42(c)(10)
  4. Baxter's media fills did not adequately simulate worst-case interventions, and its sterile-line environmental monitoring and airflow studies were inadequate.

    21 CFR 211.113(b); 21 CFR 211.42(c)(10)
  5. Baxter's manual visual inspection was inadequate because operators were not properly qualified, inspection was too fast, challenge particles were too large, and particulate complaints rose.

    21 CFR 211.160(b)

What FDA wants

FDA tells Baxter to promptly address the violations and provide independent evaluations, risk assessments, remediation plans with timelines, and CAPA (corrective and preventive action) plans for contamination, sterile operations, documentation, and visual inspection. The letter does not state a specific number of days to respond.

Who should pay attention

  • hospitals and clinics using Baxter injectable drugs
  • makers of sterile injectables with shared cephalosporin facilities
  • companies relying on visual inspection and environmental monitoring for batch release

This is a summary. Read the original letter on fda.gov.